Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:332-336
doi: 10.1161/ATVBAHA.108.182188
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pabinger, I.
Right arrow Articles by Ay, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pabinger, I.
Right arrow Articles by Ay, C.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Venous Thromboembolism
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:332.)
© 2009 American Heart Association, Inc.


Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness

Biomarkers and Venous Thromboembolism

Ingrid Pabinger; Cihan Ay

From the Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria.

Correspondence to Prof Dr Ingrid Pabinger, Professor of Hemostaseology, Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. E-mail ingrid.pabinger{at}meduniwien.ac.at

Venous thromboembolism (VTE) represents a significant health concern because of its high morbidity and mortality and is moreover characterized by high rates of recurrence. It would be useful to know biomarkers that enable early identification of patients at high or low risk of primary and recurrent VTE. Various established and novel biomarkers associated with VTE have been investigated with regard to their potential for predicting primary or recurrent VTE, for facilitating the diagnosis and for optimizing the clinical management of VTE. In this review, data on selected biomarkers (D-Dimer, soluble P-selectin, coagulation factor VIII, inflammatory markers and thrombin generation) having procoagulant properties or reflecting a prothrombotic state are summarized, and their role in clinical application is discussed.


Key Words: venous thromboembolism • recurrence • biomarker • D-Dimer • P-selectin




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. S. Wolberg and N. Mackman
Venous Thromboembolism: Risk Factors, Biomarkers, and Treatment
Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 296 - 297.
[Full Text] [PDF]